$822.51
0.10% day before yesterday
NYSE, Mar 28, 09:13 pm CET
ISIN
US5324571083
Symbol
LLY
Sector
Industry

Eli Lilly and Company Stock price

$822.51
-98.12 10.66% 1M
-63.43 7.16% 6M
+50.51 6.54% YTD
+44.55 5.73% 1Y
+530.85 182.01% 3Y
+684.07 494.13% 5Y
+748.64 1,013.46% 10Y
NYSE, Closing price Fri, Mar 28 2025
+0.84 0.10%
ISIN
US5324571083
Symbol
LLY
Sector
Industry

Key metrics

Market capitalization $779.73b
Enterprise Value $810.03b
P/E (TTM) P/E ratio 71.59
EV/FCF (TTM) EV/FCF 215.43
EV/Sales (TTM) EV/Sales 17.98
P/S ratio (TTM) P/S ratio 17.31
P/B ratio (TTM) P/B ratio 54.92
Dividend yield 0.63%
Last dividend (FY24) $5.20
Revenue growth (TTM) Revenue growth 32.00%
Revenue (TTM) Revenue $45.04b
EBIT (operating result TTM) EBIT $17.04b
Free Cash Flow (TTM) Free Cash Flow $3.76b
Cash position $3.42b
EPS (TTM) EPS $11.49
P/E forward 35.56
P/S forward 13.10
EV/Sales forward 13.61
Short interest 0.80%
Show more

Is Eli Lilly and Company a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Eli Lilly and Company Stock Analysis

Unlock Scores for Free

Analyst Opinions

30 Analysts have issued a Eli Lilly and Company forecast:

25x Buy
83%
4x Hold
13%
1x Sell
3%

Analyst Opinions

30 Analysts have issued a Eli Lilly and Company forecast:

Buy
83%
Hold
13%
Sell
3%

Financial data from Eli Lilly and Company

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
45,043 45,043
32% 32%
100%
- Direct Costs 8,418 8,418
19% 19%
19%
36,624 36,624
35% 35%
81%
- Selling and Administrative Expenses 6,827 6,827
16% 16%
15%
- Research and Development Expense 10,991 10,991
18% 18%
24%
18,807 18,807
59% 59%
42%
- Depreciation and Amortization 1,767 1,767
16% 16%
4%
EBIT (Operating Income) EBIT 17,040 17,040
65% 65%
38%
Net Profit 10,590 10,590
102% 102%
24%

In millions USD.

Don't miss a Thing! We will send you all news about Eli Lilly and Company directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Eli Lilly and Company Stock News

Positive
Reuters
about one hour ago
The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a genetically inherited risk factor for heart disease in a midstage trial, according to data presented at a major medical meeting on Sunday.
Neutral
PRNewsWire
about one hour ago
In Phase 2 ALPACA results, lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor, with some patients sustaining reductions for nearly 1.5 years These data were presented at the American College of Cardiology 2025 Scientific Sessions and simultaneously published in the New England Journal of Medicine (NEJM) INDIANAPOLIS , March 30, 2025 /PRNewswire/ -- Eli ...
Neutral
Seeking Alpha
about 11 hours ago
Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets, valued at more than $100 billion. Each of them has advantages, as well as dark spots in the pipeline of drugs and product candidates relative to the rival. Dear Seeking Alpha readers, you will discover whether Novo Nordisk or Eli Lilly is a more attractive stock in the long term.
More Eli Lilly and Company News

Company Profile

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Head office United States
CEO David Ricks
Employees 47,000
Founded 1876
Website www.lilly.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today